跳至主要内容
临床试验/CTRI/2022/12/047939
CTRI/2022/12/047939尚未招募Phase 3 4

“A clinical study to evaluate the efficacy of Takra Shirodhara along with Ksheer Bala Tail Shiro Abhyanga in the management of Raktagata Vata (Essential Hypertention)â€

Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University Jodhpur1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年10月12日最近更新:
适应症

试验速览

阶段
Phase 3 4
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
Subjective Criteria

研究概览

简要总结

Raktagata vata (Hypertension) is a type of Vata vyadhai, in which vitiation of Vata dosha in Rakta causes pain in whole body, increased Temprature, Vivarnta (discoloration), Krishta(emaciation), Aruchi (anorexia), Arunshika(boil) in whole body and Anna Stambha etc. symptoms appears. Most of efforts shows a prime role of Vata in association of remaining dosha pitta and kapha. Rraktagata vata somewhat resembles Hypertension. It is a disease of circulatory system, in which systemic arterial blood pressure elevate beyond the normal value (more then 130 /85mm of hg). In allopathy various Antihypertensive drugs like Beta blockers, Calcium channel blockers, Diuretics thiazide, ACE inhibitors are being used to decrease blood pressure, However these drugs are producing several Adverse Effects like feeling nervous erection problem. dizziness, feeling tired, headache, nausea or vomiting, so we looking to alternative system especially Ayurveda and find out solution to increase Blood Pressure. The study is open labelled Randomised to prove the efficacy of Takra Shirodhra along with Ksheer Bala tail Shiro abhyanga in the management of Raktagata vata (Essential Hypertension). In this Study 30 patients will be registered for Shiroabhyanga And Shirodhara.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
35.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • •1.Patient With Cardinal Symptoms Of Hypertension.
  • •Patient Previously Diagnosed With Hypertension, Systolic Blood Pressure Between 140-160 Mm Of Hg (Grade 1) Within 5year Prior To Start The Trial.
  • •Patient Willing To Sign The Consent Form.

排除标准

  • •Patients With Age Below 35 Years And Above 70year.
  • •Patient Having Secondary Hypertension.
  • •Patient With Malignant Hypertension I.E. Blood Pressure Above 200/140mm Of Hg.
  • •Having Any Other Serious Illness Like Coronary Artery Disease, Cerebrovascular Disease, Renal Function Impairment.

结局指标

主要结局

Subjective Criteria

时间窗: 45 days

Klama(Fatigue)

时间窗: 45 days

Hritspandan(Palpitation)

时间窗: 45 days

Objective Criteria

时间窗: 45 days

Severity Scoring Of Shiroshool (Headache)

时间窗: 45 days

Swedadhikyata(Excessive Sweating)

时间窗: 45 days

Sphygmomanometer

时间窗: 45 days

Bhrama (Giddiness)

时间窗: 45 days

Anidra(Insomnia)

时间窗: 45 days

次要结局

未报告次要终点

研究者

发起方
Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University Jodhpur
申办方类型
Government medical college

研究点 (1)

Loading locations...

相似试验